Cell of Origin and Double Protein Expression As Predictors of Outcome after Autologous Stem Cell Transplant for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation Therapy (ICT) and Autologous Stem Cell Transplant (AutoSCT)
Bradley D. Hunter(Intermountain Healthcare), Charalambos Andreadis(University of California, San Francisco), Lloyd E. Damon(University of California, San Francisco), Thomas Martin(University of California, San Francisco), Ben Rosen(Walter Reed National Military Medical Center), Weiyun Z. Ai(City College of San Francisco), Miguel Castillo(Gilead Sciences (United States)), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523